Core Viewpoint - Suzhou Fengbei Biotechnology Co., Ltd. has recently passed its IPO review and is preparing to list on the Sci-Tech Innovation Board, aiming to raise 750 million yuan [2][4]. Group 1: Company Overview - Fengbei Biotechnology focuses on the comprehensive utilization of waste resources, primarily converting waste oils into resource products [5]. - The company's main products include bio-based materials and biofuels, with applications in various sectors such as pesticides, fertilizers, and biomedicine [5]. Group 2: Financial Performance - The company's revenue for 2022, 2023, and projected for 2024 is 1.71 billion yuan, 1.73 billion yuan, and 1.948 billion yuan respectively, with net profits of 133 million yuan, 130 million yuan, and 124 million yuan [5]. - In the first half of 2025, Fengbei reported revenue of 1.478 billion yuan, a 49.62% increase from 988 million yuan in the same period last year, with a net profit of 85.06 million yuan, up 23.51% from 68.87 million yuan [8]. Group 3: IPO Details - The IPO is expected to raise 750 million yuan, which will be used for new projects including the annual production of 300,000 tons of oleic acid methyl ester and various agricultural microbial agents [3][4]. - The company has been in the IPO process for over two years, having submitted its prospectus on June 8, 2023 [4]. Group 4: Shareholding Structure - As of the IPO, Pingyuan controls 85.4% of Fengbei's shares, making it the controlling shareholder [9]. - Post-IPO, Pingyuan's shareholding will decrease to 44.82%, while other shareholders will hold the remaining shares [10].
丰倍生物IPO过会：年营收19亿 拟募资7.5亿 已交表2年多时间
Sou Hu Cai Jing·2025-08-08 03:27